Effect of Number of Replicate Electrocardiograms Recorded at Each Time Point in a Thorough QT Study on Sample Size and Study Cost

In a “thorough QT/QTc” (TQT) study, several replicate electrocardiograms (ECGs) are recorded at each time point to reduce within‐subject variability. This decreases the sample size but increases the cost of ECG analysis. To determine the most cost‐effective number of ECG replicates, the authors retr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical pharmacology 2011-06, Vol.51 (6), p.908-914
Hauptverfasser: Natekar, Mili, Hingorani, Pooja, Gupta, Pallavi, Karnad, Dilip R., Kothari, Snehal, de Vries, Michiel, ZumBrunnen, Troy, Narula, Dhiraj
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 914
container_issue 6
container_start_page 908
container_title Journal of clinical pharmacology
container_volume 51
creator Natekar, Mili
Hingorani, Pooja
Gupta, Pallavi
Karnad, Dilip R.
Kothari, Snehal
de Vries, Michiel
ZumBrunnen, Troy
Narula, Dhiraj
description In a “thorough QT/QTc” (TQT) study, several replicate electrocardiograms (ECGs) are recorded at each time point to reduce within‐subject variability. This decreases the sample size but increases the cost of ECG analysis. To determine the most cost‐effective number of ECG replicates, the authors retrospectively analyzed data from the placebo and moxifloxacin arms of a TQT study with crossover design. Six replicate ECGs were recorded at 7 time points on day −1 (baseline day), day 1, and day 3 in 124 normal healthy volunteers who were randomized to receive moxifloxacin or placebo on day 1 and the other treatment on day 3. QT interval was corrected for heart rate by the Fridericia (QTcF) and individual subject‐specific (QTcI) formulas. Within‐subject and between‐subject standard deviations for QTcF obtained by repeated‐measures analysis of covariance were 9.5 and 13.3 milliseconds with 1 replicate; 7.8 and 12.7 milliseconds with 2 replicates; 7.3 and 12.3 milliseconds with 3 replicates; 6.9 and 12.2 milliseconds with 4 replicates; 6.8 and 11.9 milliseconds with 5 replicates; and 6.6 and 11.8 milliseconds with 6 replicates. Within‐ and between‐subject variance with QTcI also declined with increasing replicates. Sample size benefit based on these estimates was negligible beyond 4 replicates. The study cost was least with 3 or 4 replicates, depending on per‐ECG and per‐subject costs.
doi_str_mv 10.1177/0091270010376962
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_865696539</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3787299671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4561-d6f2903111e55d341169fba035085f51b427deae6a9517e54fc6ee4a90eae7af3</originalsourceid><addsrcrecordid>eNqFkc9v0zAUxyMEYmVw54QsceAU8Ev8ozmiqtuYptHRwiQulpu8LN6cuLMdjXLjP8dVyw67cLDs5-_n-9WzX5a9BfoRQMpPlFZQSEqBllJUoniWTYDzImeCsufZZCfnO_0oexXCbeIE4_AyOyrolBeU8kn2Z962WEfiWnI59mv0u9M33FhT64hkbpPoXa19Y9yN131IYu18gw3Rkcx13ZGV6ZEsnBkiMQPRZNU578abjlytyDKOzZa4gSx1v7FIluY3Ej00B2HmQnydvWi1DfjmsB9n30_mq9lZfvH19Mvs80VeMy4gb0RbVLQEAOS8KRmAqNq1piVPb2k5rFkhG9QodMVBImdtLRCZrmi6lLotj7MP-9yNd_cjhqh6E2q0Vg_oxqCmgqcv5GWVyPdPyFs3-iE1p0BSkRguWaLonqq9C8Fjqzbe9NpvFVC1m456Op1keXcIHtc9No-Gf-NIANsDD85G9OHOjg_oVYfaxi7lUcpSXl5QACpSlacFkGziYDMWt__tQ53PFmesKqfJmO-NJkT89WjU_k4JWUquri9P1dWP65NiwX-q8_Iv_Oe2nw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1706653574</pqid></control><display><type>article</type><title>Effect of Number of Replicate Electrocardiograms Recorded at Each Time Point in a Thorough QT Study on Sample Size and Study Cost</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Natekar, Mili ; Hingorani, Pooja ; Gupta, Pallavi ; Karnad, Dilip R. ; Kothari, Snehal ; de Vries, Michiel ; ZumBrunnen, Troy ; Narula, Dhiraj</creator><creatorcontrib>Natekar, Mili ; Hingorani, Pooja ; Gupta, Pallavi ; Karnad, Dilip R. ; Kothari, Snehal ; de Vries, Michiel ; ZumBrunnen, Troy ; Narula, Dhiraj</creatorcontrib><description>In a “thorough QT/QTc” (TQT) study, several replicate electrocardiograms (ECGs) are recorded at each time point to reduce within‐subject variability. This decreases the sample size but increases the cost of ECG analysis. To determine the most cost‐effective number of ECG replicates, the authors retrospectively analyzed data from the placebo and moxifloxacin arms of a TQT study with crossover design. Six replicate ECGs were recorded at 7 time points on day −1 (baseline day), day 1, and day 3 in 124 normal healthy volunteers who were randomized to receive moxifloxacin or placebo on day 1 and the other treatment on day 3. QT interval was corrected for heart rate by the Fridericia (QTcF) and individual subject‐specific (QTcI) formulas. Within‐subject and between‐subject standard deviations for QTcF obtained by repeated‐measures analysis of covariance were 9.5 and 13.3 milliseconds with 1 replicate; 7.8 and 12.7 milliseconds with 2 replicates; 7.3 and 12.3 milliseconds with 3 replicates; 6.9 and 12.2 milliseconds with 4 replicates; 6.8 and 11.9 milliseconds with 5 replicates; and 6.6 and 11.8 milliseconds with 6 replicates. Within‐ and between‐subject variance with QTcI also declined with increasing replicates. Sample size benefit based on these estimates was negligible beyond 4 replicates. The study cost was least with 3 or 4 replicates, depending on per‐ECG and per‐subject costs.</description><identifier>ISSN: 0091-2700</identifier><identifier>EISSN: 1552-4604</identifier><identifier>DOI: 10.1177/0091270010376962</identifier><identifier>PMID: 20852005</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Aza Compounds - adverse effects ; cardiac repolarization ; Cost-Benefit Analysis ; drug-induced QT prolongation ; Electrocardiography ; Electrocardiography - drug effects ; Electrocardiography - economics ; Electrocardiography - statistics &amp; numerical data ; Female ; Fluoroquinolones ; Humans ; IKR channel ; Male ; Middle Aged ; Quinolines - adverse effects ; Sample Size ; Toxicity Tests, Acute - economics ; Toxicity Tests, Acute - methods</subject><ispartof>Journal of clinical pharmacology, 2011-06, Vol.51 (6), p.908-914</ispartof><rights>2011 American College of Clinical Pharmacology</rights><rights>2011 SAGE Publications</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4561-d6f2903111e55d341169fba035085f51b427deae6a9517e54fc6ee4a90eae7af3</citedby><cites>FETCH-LOGICAL-c4561-d6f2903111e55d341169fba035085f51b427deae6a9517e54fc6ee4a90eae7af3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1177%2F0091270010376962$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1177%2F0091270010376962$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20852005$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Natekar, Mili</creatorcontrib><creatorcontrib>Hingorani, Pooja</creatorcontrib><creatorcontrib>Gupta, Pallavi</creatorcontrib><creatorcontrib>Karnad, Dilip R.</creatorcontrib><creatorcontrib>Kothari, Snehal</creatorcontrib><creatorcontrib>de Vries, Michiel</creatorcontrib><creatorcontrib>ZumBrunnen, Troy</creatorcontrib><creatorcontrib>Narula, Dhiraj</creatorcontrib><title>Effect of Number of Replicate Electrocardiograms Recorded at Each Time Point in a Thorough QT Study on Sample Size and Study Cost</title><title>Journal of clinical pharmacology</title><addtitle>J Clin Pharmacol</addtitle><description>In a “thorough QT/QTc” (TQT) study, several replicate electrocardiograms (ECGs) are recorded at each time point to reduce within‐subject variability. This decreases the sample size but increases the cost of ECG analysis. To determine the most cost‐effective number of ECG replicates, the authors retrospectively analyzed data from the placebo and moxifloxacin arms of a TQT study with crossover design. Six replicate ECGs were recorded at 7 time points on day −1 (baseline day), day 1, and day 3 in 124 normal healthy volunteers who were randomized to receive moxifloxacin or placebo on day 1 and the other treatment on day 3. QT interval was corrected for heart rate by the Fridericia (QTcF) and individual subject‐specific (QTcI) formulas. Within‐subject and between‐subject standard deviations for QTcF obtained by repeated‐measures analysis of covariance were 9.5 and 13.3 milliseconds with 1 replicate; 7.8 and 12.7 milliseconds with 2 replicates; 7.3 and 12.3 milliseconds with 3 replicates; 6.9 and 12.2 milliseconds with 4 replicates; 6.8 and 11.9 milliseconds with 5 replicates; and 6.6 and 11.8 milliseconds with 6 replicates. Within‐ and between‐subject variance with QTcI also declined with increasing replicates. Sample size benefit based on these estimates was negligible beyond 4 replicates. The study cost was least with 3 or 4 replicates, depending on per‐ECG and per‐subject costs.</description><subject>Adult</subject><subject>Aza Compounds - adverse effects</subject><subject>cardiac repolarization</subject><subject>Cost-Benefit Analysis</subject><subject>drug-induced QT prolongation</subject><subject>Electrocardiography</subject><subject>Electrocardiography - drug effects</subject><subject>Electrocardiography - economics</subject><subject>Electrocardiography - statistics &amp; numerical data</subject><subject>Female</subject><subject>Fluoroquinolones</subject><subject>Humans</subject><subject>IKR channel</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Quinolines - adverse effects</subject><subject>Sample Size</subject><subject>Toxicity Tests, Acute - economics</subject><subject>Toxicity Tests, Acute - methods</subject><issn>0091-2700</issn><issn>1552-4604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9v0zAUxyMEYmVw54QsceAU8Ev8ozmiqtuYptHRwiQulpu8LN6cuLMdjXLjP8dVyw67cLDs5-_n-9WzX5a9BfoRQMpPlFZQSEqBllJUoniWTYDzImeCsufZZCfnO_0oexXCbeIE4_AyOyrolBeU8kn2Z962WEfiWnI59mv0u9M33FhT64hkbpPoXa19Y9yN131IYu18gw3Rkcx13ZGV6ZEsnBkiMQPRZNU578abjlytyDKOzZa4gSx1v7FIluY3Ej00B2HmQnydvWi1DfjmsB9n30_mq9lZfvH19Mvs80VeMy4gb0RbVLQEAOS8KRmAqNq1piVPb2k5rFkhG9QodMVBImdtLRCZrmi6lLotj7MP-9yNd_cjhqh6E2q0Vg_oxqCmgqcv5GWVyPdPyFs3-iE1p0BSkRguWaLonqq9C8Fjqzbe9NpvFVC1m456Op1keXcIHtc9No-Gf-NIANsDD85G9OHOjg_oVYfaxi7lUcpSXl5QACpSlacFkGziYDMWt__tQ53PFmesKqfJmO-NJkT89WjU_k4JWUquri9P1dWP65NiwX-q8_Iv_Oe2nw</recordid><startdate>201106</startdate><enddate>201106</enddate><creator>Natekar, Mili</creator><creator>Hingorani, Pooja</creator><creator>Gupta, Pallavi</creator><creator>Karnad, Dilip R.</creator><creator>Kothari, Snehal</creator><creator>de Vries, Michiel</creator><creator>ZumBrunnen, Troy</creator><creator>Narula, Dhiraj</creator><general>Blackwell Publishing Ltd</general><general>SAGE Publications</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201106</creationdate><title>Effect of Number of Replicate Electrocardiograms Recorded at Each Time Point in a Thorough QT Study on Sample Size and Study Cost</title><author>Natekar, Mili ; Hingorani, Pooja ; Gupta, Pallavi ; Karnad, Dilip R. ; Kothari, Snehal ; de Vries, Michiel ; ZumBrunnen, Troy ; Narula, Dhiraj</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4561-d6f2903111e55d341169fba035085f51b427deae6a9517e54fc6ee4a90eae7af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aza Compounds - adverse effects</topic><topic>cardiac repolarization</topic><topic>Cost-Benefit Analysis</topic><topic>drug-induced QT prolongation</topic><topic>Electrocardiography</topic><topic>Electrocardiography - drug effects</topic><topic>Electrocardiography - economics</topic><topic>Electrocardiography - statistics &amp; numerical data</topic><topic>Female</topic><topic>Fluoroquinolones</topic><topic>Humans</topic><topic>IKR channel</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Quinolines - adverse effects</topic><topic>Sample Size</topic><topic>Toxicity Tests, Acute - economics</topic><topic>Toxicity Tests, Acute - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Natekar, Mili</creatorcontrib><creatorcontrib>Hingorani, Pooja</creatorcontrib><creatorcontrib>Gupta, Pallavi</creatorcontrib><creatorcontrib>Karnad, Dilip R.</creatorcontrib><creatorcontrib>Kothari, Snehal</creatorcontrib><creatorcontrib>de Vries, Michiel</creatorcontrib><creatorcontrib>ZumBrunnen, Troy</creatorcontrib><creatorcontrib>Narula, Dhiraj</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Natekar, Mili</au><au>Hingorani, Pooja</au><au>Gupta, Pallavi</au><au>Karnad, Dilip R.</au><au>Kothari, Snehal</au><au>de Vries, Michiel</au><au>ZumBrunnen, Troy</au><au>Narula, Dhiraj</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Number of Replicate Electrocardiograms Recorded at Each Time Point in a Thorough QT Study on Sample Size and Study Cost</atitle><jtitle>Journal of clinical pharmacology</jtitle><addtitle>J Clin Pharmacol</addtitle><date>2011-06</date><risdate>2011</risdate><volume>51</volume><issue>6</issue><spage>908</spage><epage>914</epage><pages>908-914</pages><issn>0091-2700</issn><eissn>1552-4604</eissn><abstract>In a “thorough QT/QTc” (TQT) study, several replicate electrocardiograms (ECGs) are recorded at each time point to reduce within‐subject variability. This decreases the sample size but increases the cost of ECG analysis. To determine the most cost‐effective number of ECG replicates, the authors retrospectively analyzed data from the placebo and moxifloxacin arms of a TQT study with crossover design. Six replicate ECGs were recorded at 7 time points on day −1 (baseline day), day 1, and day 3 in 124 normal healthy volunteers who were randomized to receive moxifloxacin or placebo on day 1 and the other treatment on day 3. QT interval was corrected for heart rate by the Fridericia (QTcF) and individual subject‐specific (QTcI) formulas. Within‐subject and between‐subject standard deviations for QTcF obtained by repeated‐measures analysis of covariance were 9.5 and 13.3 milliseconds with 1 replicate; 7.8 and 12.7 milliseconds with 2 replicates; 7.3 and 12.3 milliseconds with 3 replicates; 6.9 and 12.2 milliseconds with 4 replicates; 6.8 and 11.9 milliseconds with 5 replicates; and 6.6 and 11.8 milliseconds with 6 replicates. Within‐ and between‐subject variance with QTcI also declined with increasing replicates. Sample size benefit based on these estimates was negligible beyond 4 replicates. The study cost was least with 3 or 4 replicates, depending on per‐ECG and per‐subject costs.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>20852005</pmid><doi>10.1177/0091270010376962</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0091-2700
ispartof Journal of clinical pharmacology, 2011-06, Vol.51 (6), p.908-914
issn 0091-2700
1552-4604
language eng
recordid cdi_proquest_miscellaneous_865696539
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Adult
Aza Compounds - adverse effects
cardiac repolarization
Cost-Benefit Analysis
drug-induced QT prolongation
Electrocardiography
Electrocardiography - drug effects
Electrocardiography - economics
Electrocardiography - statistics & numerical data
Female
Fluoroquinolones
Humans
IKR channel
Male
Middle Aged
Quinolines - adverse effects
Sample Size
Toxicity Tests, Acute - economics
Toxicity Tests, Acute - methods
title Effect of Number of Replicate Electrocardiograms Recorded at Each Time Point in a Thorough QT Study on Sample Size and Study Cost
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T10%3A22%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Number%20of%20Replicate%20Electrocardiograms%20Recorded%20at%20Each%20Time%20Point%20in%20a%20Thorough%20QT%20Study%20on%20Sample%20Size%20and%20Study%20Cost&rft.jtitle=Journal%20of%20clinical%20pharmacology&rft.au=Natekar,%20Mili&rft.date=2011-06&rft.volume=51&rft.issue=6&rft.spage=908&rft.epage=914&rft.pages=908-914&rft.issn=0091-2700&rft.eissn=1552-4604&rft_id=info:doi/10.1177/0091270010376962&rft_dat=%3Cproquest_cross%3E3787299671%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1706653574&rft_id=info:pmid/20852005&rfr_iscdi=true